On optimal delivery of combination therapy for tumors

Mathematical Biosciences

Volumn 222, Issue 1, 2009, Pages 13-26

  d'Onofrio, Alberto ^a   Ledzewicz, Urszula ^b   Maurer, Helmut ^c   Schättler, Heinz ^d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

Anti angiogenesis; Chemotherapy; Combination therapy for tumors; Mathematical model; Optimal control

Indexed keywords

ANTI-ANGIOGENESIS; CHEMOTHERAPEUTIC AGENTS; COMBINATION THERAPY; COMBINATION THERAPY FOR TUMORS; CYTOTOXIC DRUGS; NUMERICAL RESULTS; OPTIMAL CONTROL; OPTIMAL CONTROL PROBLEM; OPTIMAL CONTROLS; OPTIMAL SCHEDULING;

CHEMOTHERAPY; COMPUTER SIMULATION; ONCOLOGY; OPTIMIZATION; SCHEDULING; TUMORS;

MATHEMATICAL MODELS;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT;

CHEMOTHERAPY; INHIBITOR; NUMERICAL MODEL; TUMOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; DRUG DOSE REGIMEN; ENDOTHELIUM CELL; ERADICATION THERAPY; MATHEMATICAL MODEL; MONOTHERAPY; NONHUMAN; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NUMERICAL ANALYSIS, COMPUTER-ASSISTED;

EID: 70350339795     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2009.08.004     Document Type: Article

References (62)

1. Folkman J. Antiangiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175 (1972) 409
2. Klagsburn M., and Soker S. VEGF/VPF: the angiogenesis factor found?. Curr. Biol. 3 (1993) 699
3. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404
4. Kerbel R.S. A cancer therapy resistant to resistance. Nature 390 (1997) 335
5. Chaplain M., and Anderson A. The mathematical modelling, simulation and prediction of tumour-induced angiogenesis. Invas. Metast. 16 (1997) 222
6. Anderson A., and Chaplain M. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 60 (1998) 857
7. Arakelyan L., Vainstain V., and Agur Z. A computer algorithm describing the process of vessel, rmation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumour growth. Angiogenesis 5 (2002) 203
8. Alarcon T., Owen M.R., Byrne H.M., and Maini P.K. Multiscale modelling of tumour growth and therapy: the influence of vessel normalisation on chemotherapy. Comput. Math. Meth. Med. 7 (2006) 85
9. Bartha K., and Rieger H. Vascular network remodelling via vessel cooption, regression and growth in tumours. J. Theor. Biol. 241 (2006) 903
10. Capasso V., and Morale D. Stochastic modelling of tumour induced angiogenesis. J. Math. Biol. 58 (2009) 219
11. Hahnfeldt P., Panigrahy D., Folkman J., and Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth treatment, response, and postvascular dormancy. Cancer Res. 59 (1999) 4770
12. Ergun A., Camphausen K., and Wein L.M. Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 65 (2003) 407
13. d'Onofrio A., and Gandolfi A. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. Math. Biosci. 191 (2004) 159
14. Forys U., Keifetz Y., and Kogan Y. Critical-point analysis for three-variable cancer angiogenesis models. Math. Biosci. Eng. 2 (2005) 511
15. Stamper I.J., Byrne H.M., Owen M.R., and Maini P.K. Modelling the role of angiogenesis vasculogenesis in solid tumour growth. Bull. Math. Biol. 69 (2007) 2737
16. d'Onofrio A., and Gandolfi A. The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation. Appl. Math. Comput. 181 (2006) 1155
17. U. Ledzewicz, H. Schättler, A synthesis of optimal controls for a model of tumor growth under angiogenic inhibitors, in: Proceedings of the 44th IEEE Conference on Dec. and Control, Sevilla, Spain, 2005, pp. 945-950.
18. U. Ledzewicz, H. Schättler, Application of optimal control to a system describing tumor anti-angiogenesis, in: Proceedings of the 17th International Symposium on Mathematical Theory of Networks and Systems (MTNS), Kyoto, Japan, July 2006, pp. 478-484.
19. Ledzewicz U., and Schättler H. Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J. Control Optim. 46 (2007) 1052
20. Ledzewicz U., and Schättler H. Analysis of a mathematical model for tumor anti-angiogenesis. Opt. Control Appl. Meth. 29 1 (2008) 41
21. Ledzewicz U., and Schättler H. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. J. Theor. Biol. 252 (2008) 295
22. Ledzewicz U., and Schättler H. On the optimality of singular controls for a class of mathematical models for tumor anti-angiogenesis. Disc. Cont. Dyn. Syst. Ser. B 11 (2009) 691
23. Ledzewicz U., Munden J., and Schättler H. Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models. Disc. Cont. Dyn. Syst. Ser. B 12 (2009) 415
24. A. Swierniak, A. d'Onofrio, A. Gandolfi, Control problems related to tumor angiogenesis, in: Proceedings of the IECON 2006, IEEE Press, New York, 2006, pp. 677-681.
25. Swierniak A. Direct and indirect control of cancer populations. Bull. Pol. Acad. Sci. Technol. Sci. 56 (2008) 367
26. Eisen M. Mathematical models in cell biology and cancer chemotherapy. Lecture Notes in Biomathematics vol. 30 (1979), Springer, Berlin
27. A. Swierniak, Optimal treatment protocols in leukemia - modelling the proliferation cycle, in: Proceedings of the 12th IMACS World Congress, Paris, vol. 4, 1988, pp. 170-172.
28. Swan G.W. Role of optimal control in cancer chemotherapy. Math. Biosci. 101 (1990) 237
29. Swierniak A. Cell cycle as an object of control. J. Biol. Syst. 3 (1995) 41
30. Swierniak A., Polanski A., and Kimmel M. Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Prolif. 29 (1996) 17
31. Fister K.R., and Panetta J.C. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math. 60 (2000) 1059
32. Ledzewicz U., and Schättler H. Optimal bang-bang controls for a two-compartment model in cancer chemotherapy. J. Optim. Theor. Appl. - JOTA 114 (2002) 609
33. Ledzewicz U., and Schättler H. Analysis of a cell-cycle-specific model for cancer chemotherapy. J. Biol. Syst. 10 (2002) 183
34. Swierniak A., Ledzewicz U., and Schättler H. Optimal control for a class of compartmental models in cancer chemotherapy. Int. J. Appl. Math. Comput. Sci. 13 (2003) 357
35. Kimmel M., and Swierniak A. Control theory approach to cancer chemotherapy: benefiting from phase dependence and overcoming drug resistance. In: Friedman A. (Ed). Tutorials in Mathematical Bioscences III: Cell Cycle Proliferation and Cancer Lecture Notes in Mathematics vol. 1872 (2006), Springer, Heidelberg 185
36. Ledzewicz U., and Schättler H. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy. Math. Biosci. 206 (2007) 320
37. Kirschner D., Lenhart S., and Serbin S. Optimal control of chemotherapy of HIV. J. Math. Biol. 35 (1997) 775
38. Castiglione F., and Piccoli B. Optimal control in a model of dendritic cell transfection cancer immunotherapy. Bull. Math. Biol. 68 (2006) 255
39. de Pillis L.G., and Radunskaya A. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. J. Theor. Med. 3 (2001) 79
40. d'Onofrio A. Rapidly acting antitumoral anti-angiogenic therapies. Phys. Rev. E 76 3 (2007) 031920
41. A. Swierniak, Modelling combined angiogenic and chemotherapy, in: Proceedings of the 14th National Conference on Application of Mathematical in Biology and Medicine, Leszno, Poland, 2008, pp. 127-133.
42. Wheldon T.E. Mathematical Models in Cancer Research (1988), Hilger, Boston, MA
43. Sachs R.K., Hlatky L.R., and Hahnfeldt P. Simple ODE models of tumor growth and anti-angiogenic or radiation treatment. Math. Comput. Mod. 33 (2001) 1297
44. d'Onofrio A., Gandolfi A., and Rocca A. The dynamics of tumour-vasculature interaction suggests low-dose, time-dense antiangiogenic schedulings. Cell Prolif. 42 (2009) 317
45. d'Onofrio A. Fractal growth of tumors and other cellular populations: linking the mechanistic to the phenomenological modeling and vice versa. Chaos, Sol. Frac. 41 (2009) 875
46. d'Onofrio A. A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208 (2005) 220
47. Mombach J.C.M., Lemke N., Bodmann B.E.J., and Idiart M.A.P. A mean-field theory of cellular growth. Europhys. Lett. 59 (2002) 923
48. d'Onofrio A., and Cerrai A. A bi-parametric model for the tumour angiogenesis and antiangiogenesis therapy. Math. Comput. Model. 49 (2009) 1156
49. d'Onofrio A., and Gandolfi A. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. Math. Med. Biol. 26 (2009) 63
50. Tee D., and Di Stefano III J. Simulation of tumour-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies. J. Cancer Res. Clin. Oncol. 130 (2004) 15
51. Kohandel M., Kardar M., Sivaloganathan S., and Milosevic M. Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies. Phys. Med. Biol. 52 (2007) 3665
52. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878
53. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nole F., Peruzzotti G., Robertson C., Orlando L., Cinieri S., de Braud F., Viale G., and Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumour activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13 (2002) 73
54. Wijeratne N.S., and Hoo K.A. Understanding the role of the tumour vasculature in the transport of drugs to solid cancer tumors. Cell Prolif. 40 (2007) 283
55. U. Ledzewicz, H. Schättler, A. d'Onofrio, Optimal control for combination therapy in cancer, in: Proceedings of the 47th IEEE Conference on Dec. and Control, Cancun, Mexico, 2008, pp. 1537-1542.
56. Bressan A., and Piccoli B. Introduction to the Mathematical Theory of Control (2007), American Institute of Mathematical Sciences
57. Bonnard B., and Chyba M. Singular trajectories and their role in control theory. Mathématiques & Applications vol. 40 (2003), Springer, Paris
58. C. Büskens, Optimierungsmethoden und Sensitivitätsanalyse für optimale Steuerprozesse mit Steuer- und Zustands-Beschränkungen, Dissertation, Institut für Numerische Mathematik, Universität Münster, 1998.
59. Büskens C., and Maurer H. Sensitivity analysis and real-time optimization of parametric nonlinear programming problems. In: Grötschel M., et al. (Ed). Online Optimization of Large Scale Systems (2001), Springer, Berlin 3
60. Büskens C., and Maurer H. SQP-methods for solving optimal control problems with control and state constraints: adjoint variables, sensitivity analysis and real-time control. J. Comput. Appl. Math. 120 (2000) 85
61. Maurer H., Büskens C., Kim J.-H.R., and Kaya C.Y. Optimization methods for the verification of second order sufficient conditions for bang-bang controls. Opt. Control Appl. Meth. 26 (2005) 129
62. U. Ledzewicz, J. Marriott, H. Maurer, H. Schättler, Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment, Math. Med. Biol., in press.